Treatment for COVID-19 included monoclonal antibodies (mAbs) targeting the spike protein (bamlanivimab and casirivimab/imdevimab) (median days after symptom debut: 7 days, range 6–19), convalescent plasma from recovered patients (median days after symptom debut: 15.5 days, range 5–86), corticosteroids (median days after symptom debut: 8 days, range 4–37), and anti-viral remdesivir (median days after symptom debut: 6 days, range 3–70). The gene discussed is CHMP5; the disease is COVID-19.